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The results of own investigations and literature data are summarized to determine the place of the main methods of adsorption 
therapy in complex treatment of the patients with malignant tumors. New possibilities for the usage of new generation of carbon 
adsorbents and modern adsorptive technologies in cancer treatment are discussed.
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Severe toxicosis observed in cancer patients 
is manifested by many clinical symptoms including 
general asthenia, elevated fatigability, adynamia, labil-
ity of pulse and pressure, nausea, vomiting, disturbed 
appetites up to complete anorexia, diarrhea, skin pallor 
and sallow, xerostomia, xidrosis, fever, myalgia and 
ostealgia, inclination to peripheral neuropathy, psychic 
inhibition, cephalalgia and faintness, sleep disorder, 
anemia, decreased staminas to infectious diseases, 
dystrophy of muscle tissue and progressive body 
weight loss with final cancer cachexia. The spectrum 
of mentioned symptoms in each particular case could 
vary dependent on the patterns of clinical course of the 
disease, intensity of destructive processes, treatment 
type, presence of concurrent diseases and complica-
tions, and many other conditions.
Oncological toxicosis is based on several factors. 
Firstly, it is “tumor disposition”, i.e. a special pathologi-
cal state that develops during the process of natural 
course of malignant disease and is caused by distant 
character of tumors’ influence on metabolism and host 
immune status [1–3]. Secondly, tumor-dependent 
compression or tumor invasion into vital organs and 
malfunction of excretory-evacuation systems, and also 
“overloading” of cellular and humoral blood transport 
agents with waste metabolites lead to expressed 
disturbance of biochemical homeostasis and meta-
bolic intoxication [4, 5, 6]. The third cause of toxicosis 
is originated due to the treatment directed on the 
destruction of neoplastic lesions [7–11]. A certain role 
is played also by unspecific factors such as surgical 
trauma, hemorrhagia, inflammatory complications, 
and sepsis [12, 13]. 
In accordance with abovementioned, in oncological 
clinics adsorptive therapy could be applied:
•	to remove toxins generated in the process of 
“natural” tumor-host interaction;
•	for correction of metabolic intoxication;
•	for sorption of toxins that accumulate due to the 
destruction/damage of normal and tumor cells 
with different therapeutic agents, including ir-
radiation;
•	for local and systemic control of pharmacokinet-
ics of cytostatic preparations;
•	for therapy of surgical complications and con-
cominant toxicosis, for instance, bacterial en-
dotoxicosis of enteric origin that accompanies 
massive blood loss.
These possibilities are realized by the use of three 
main methods of sorption therapy, namely: hemo-
sorption (HS), enterosorption (ES) and application 
sorption (AS).
TYPES AND CHARACTERISTICS 
OF CARBON ADSORBENTS
Two types of carbon adsorbents — granulated and 
fibrous ones — are used in adsorptive therapy. Well-
known SCN carbons prepared on the basis of synthetic 
polymeric resins and possessing developed porous 
structure, specific surface of the order of 1.5 thou-
sands m2/g and high enough adsorption activity, 
belong to the first type. New generation of granulated 
carbon adsorbents with specific surface that reaches 
3.5 thousands m2/g, has been developed in the De-
partment of Physico-Chemical Mechanisms of Sorp-
tion Detoxification of IEPOR NASU and was registered 
in Ukraine and Uzbekistan under HSGD mark (Hemo 
Sorbents Granulated Deliganding). HSGD, due to ef-
fective removal of protein-bound toxic metabolites 
such as nonconjugated bilirubin, free fatty acids, 
phenols, bile acids, mercaptanes, and a whole num-
ber of uremic and burn toxins during hemosorption 
procedure, allow to achieve qualitatively new thera-
peutic effects related to deep purification of transport 
proteins and blood cell membranes [14, 15]. Clinical 
use of HSGD columns as a module of “Artificial liver” 
apparatus or as a separate system for prehepatocytic 
removal of bile components and their precursors al-
lows remove apiece up to 1 g of bilirubin, with the use 
of column that contains by 20–30 times lower sorbent 
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mass than reactors of other modern systems for treat-
ment of hepatic insufficiency.
These super active carbon adsorbents effectively 
remove also proinflammatory cytokines and could 
be used for treatment of practically all states associ-
ated with the development of Systemic Inflamatory 
Response Syndrom (SIRS) [16].
Activated fibrous carbon adsorbents for medical 
purposes that possess high sorption activity too (their 
specific surface is in a range from 1.5 to 2.5 thousands 
m2/g), are used mainly as a basis for preparation of en-
terosorbents and application sorbents. In the process 
of production of modern enterosorbents of IV gen-
eration — “Carboline”, activated carbon fibrous ma-
terials are dissected into 40–50 nm fibers which are 
used for formation of tablets or granules with the use 
of water as a binding element; this allows to preserve 
completely preserve the capacity of the sorbent and 
significantly improve its kinetic parameters.
Both granulated and fibrous adsorbents may serve 
as a matrix for immobilization of biologically active 
compounds without using additional cross-linking 
agents — “binary synthesis”. This method has been 
used for immobilization of native thymus DNA and 
dextrane sulphate onto granulated and fibrous car-
bon adsorbents [16]. Coating of superactive carbon 
matrix with native DNA allows not only to remove DNA-
binding compounds that could be present in excessive 
amounts, for instance in blood of patients with lung 
cancer or hepatocellular carcinoma, but also signifi-
cantly intensifies the elimination of proinflammatory 
cytokines (TNF-α, IL-1, IL-6). An expressed antitu-
mor effect has been registered in 6 from 7 dogs with 
spontaneous tumors of mammary gland after plas-
moimmunosorption on highly active carbon fibers with 
immobilized devitalized St. aureus Cowans I cells [17]. 
Meanwhile, in 3 animals complete tumor reduction 
and healing of superficial wounds has been achieved.
CARBON ADSORBENTS IN CANCER 
TREATMENT
Presently a certain experience of the use of carbon 
adsorbents in combined therapy of cancer has been 
accumulated.
Carbon adsorbents in surgery
 In surgery adsorptive therapy is directed on prepa-
ration of patients with severe intoxication to surgical 
intervention and elimination of post-surgical purulent-
septic complications.
The performance of one or few HS sessions in pa-
tients with mechanical jaundice at pre-surgical period 
allows carrying out extensive surgery without specific 
complications characteristic for long-term cholemia. 
After HS in the patients, concentration of bilirubin, 
bile acids and creatinin decreases, and skin itching 
vanishes or decreases [18]. HS partially or completely 
prevents post-surgical fall of fibrinogen level that could 
be a cause of elevated hemorrhage. The positive effect 
of HS in patients with mechanical jaundice is in part 
related to the removal of bacterial endotoxins that pass 
to systemic blood flow due to malfunction of natural 
mechanism of their decontamination by conjugation 
with bile acids. The clinical experience has demon-
strated that HS in patients with mechanical jaundice 
is the most effective if it is performed one day prior 
to the surgical intervention. In this case the sorbent 
of choice is HSGD that allows removing large quantities 
of protein-bound cholemic metabolites.
Modern tactics of treatment of patients with me-
chanic jaundice of cancer genesis is based on com-
bination of intense infusion therapy with the use 
of extracorporeal detoxification methods including 
HS, plasmapheresis, and blood perfusion through 
xenospleen, that allows reduce early post-surgical 
mortality by 8.5% [19]. The efficacy of plasmapheresis 
and HS increases if the procedures are performed after 
endoscopic detoxification of biliary tract [20].
An alternative means of pre-surgical preparation 
of cancer patients with liver and kidney malfunction 
is massive ES (8–24 tablets of “Carboline” entero-
sorbent per day) that provides quick decrease of in-
toxication level and improvement of overall health. 
In patients with mechanical jaundice the use of carbon 
enterosorbents at pre-surgical period was accompa-
nied by improvement of hepato-renal functions thus 
allowing to reduce significantly the number of purulent 
post-surgical complications and lethal outcomes [21].
In principle, prophylactic ES could be indicated 
in all the cases when surgical intervention is related 
to the risk of massive blood loss that leads to central-
ization of blood circulation and effluent of E.coli endo-
toxin in blood with the next development of SIRS. Then 
the presence of large amounts of fibrous carbon 
enterosorbents in large bowel impedes the develop-
ment of systemic endotoxicosis and uncorrectable 
hypotension.
HS is an effective element of complex therapy 
of post-surgical purulent-septic complications. 
In patients with a generalized peritonitis after surgery 
related to gastric cancer and cancer of pancreato-
duodenal region, HS promotes quick restoration 
of intestinal peristalsis, decrease of purulent egestas 
from abdominal cavity and elimination of peritoneal 
symptoms, improvement of functional state of liver 
and kidneys, cardio-vascular system and rheologic 
properties of blood, that results in statistically sig-
nificant decrease of lethal outcomes [22]. An analysis 
of efficacy of treatment of patients with a generalized 
peritonitis has shown that HS should be performed 
in the first 12–36 hours after laparotomy.
During HS process, in patient blood the level 
of toxic metabolites including medium molecular 
weight peptides, decreases, what is caused not only 
by their effective removal but also by the decrease 
of total proteolytic activity of blood plasma. A posi-
tive consequence of HS is elevation of blood content 
of mature neutrophils that could be possible caused 
by de-suppression of active proliferation of stem cells 
inhibited by toxic factors. The contact of blood cells 
with the sorbent may cause transitory degranulation 
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of neutrophils and 100–200-fold increase of lactoferrin 
level that participates in hemopoiesis regulation, inac-
tivation and elimination of medium molecular weight 
toxins, in blood plasma. Effluent of myeloperoxidase 
and lysozyme in blood flow elevates tumoricidal and 
bactericidal potential of blood. During HS process 
with the use of deliganding adsorbents, there oc-
curs an intense “purification” of cellular membranes, 
removal of protein-bound metabolites and correction 
of transport functions of proteins and erythrocytes.
Detoxification abilities of ES at post-surgical pe-
riod have been demonstrated with the use of mixed 
sorbent (polysorb with microcellulose) in the patients 
with colorectal cancer [23]. Three weeks after surgi-
cal intervention, in the ES-treated patients the level 
of immune complexes was at average by 28% lower 
that that in control group.
A significant role in post-surgical treatment of can-
cer patients could be played by AS. Presently there are 
developed the approaches for the use of applicative ad-
sorbents at different stages of wound process. At early 
post-surgical period the AC method provides quick 
sorption of a large quantity (up to 1.5 g per 1 g of the 
weight of carbon tissue) of different biologically ac-
tive components from wound, for instance, biogenic 
amines and mediators of inflammation, as well as toxic 
products, that leads to attenuation of vascular reaction 
and intensity of inflammatory events in the wound and 
surrounding tissues, blocks local sources of intoxica-
tion and prevents secondary infection [24]. Finally 
the terms of wound healing are reduced. For cancer 
patients an early AS use is especially relevant because 
surgical intervention performed at the background 
of intoxication and decreased activity of detoxifica-
tion systems, often leads to purulent-inflammatory 
complications.
For treatment of wounds already complicated with 
purulent infection, sorption-enzymatic complex on the 
basis of fibrous carbon sorbents with immobilized 
proteolytic enzymes is of special interest. Immobiliza-
tion of enzymes could be done also ex tempore from 
enzyme solution (0.1 g of enzyme per 50 ml of physi-
ologic solution or solution of antiseptics, for instance, 
chlorhexidine). Such binary system provides effective 
enzymatic lysis of wound dedritis and denatured pro-
teins and sorption of proteolytic products and tissue 
toxins. Also, immobilization prevents quick inactivation 
of enzymes in the wound while decreased viscosity and 
elevation of osmolarity of wound content upon the ac-
tion of proteases improves draining properties of car-
bon material. Carbon fibrous sorbents could serve 
as a matrix for immobilization of antibiotics including 
anticancer ones what guarantee the stability of their 
concentration and the place of contact with wound 
surface. This allows consider such composites as the 
means of local chemotherapy. For instance, in a half 
of cases tumor cells are found in peritoneal lavage 
of patients with gastric cancer. In such situation intra-
peritoneal chemotherapy with high local concentration 
of cytostatics may serve as an effective supplement 
to surgical treatment.
Carbon adsorbents in chemotherapy
Intense chemotherapy up-to-date remains the 
most aggressive method of treatment of cancer 
patients. High systemic toxicity of anticancer means 
leading to nephro- and cardiopathy, hepatic and 
gastro-intestinal insufficiency, suppression of hemo-
poiesis, in a number of cases hinders the performance 
of chemotherapy courses at the required dose.
During preparation of cancer patients to intense 
chemotherapy courses and radiation therapy one 
could use HS or ES methods depending on the endog-
enous intoxication degree and the presence of com-
plications of tumor process that could be considered 
as contraindications to HS performance (risk of uncon-
trolled internal hemorrhage, pulmonary edema, and 
expressed hypotension). Adsorptive therapy improves 
patient’s state, obviates asthenia, nausea and vomit-
ing, sleeping disorders, eliminates or attenuates tumor 
anorexia syndrome.
HS at the background of massive chemotherapy 
accompanied by renal and hepatic insufficiency 
and cytostatic-dependent myelodepression allows 
to decrease significantly clinical signs of intoxication, 
improve function of kidneys and liver, elevate at aver-
age by 10% leukocyte blood counts and enables the 
treatment continuation by radical schemes [25].
In HS process, deliganding sorbents may provide 
effective removal of protein-bound hepatic and ure-
mic toxins upon cytostatic hepatitis and myocarditis, 
as well as renal complications of chemotherapy.
Control of pharmacokinetic of cytostatics
HS method affords unique possibilities for control 
of pharmacokinetics of antineoplastic drugs. Thera-
peutically valuable differences between concentra-
tions of cytostatics in tumor and the most vulnerable 
organs are created by regional introduction of massive 
preparation doses with the following adsorption purifi-
cation of flowing blood. Just in 70th years of last century 
there have been proposed two principal schemes 
of regional chemotherapy that anticipate an effective 
defense of systemic blood flow with the use of HS [26].
In the first scheme intraarterial chemotherapy 
is accompanied with adsorption purification of flow-
ing blood under blocking the vessels that unite re-
gional circle with the body. Analogous approach could 
be used in other variants of local chemotherapy where 
blood flow “regionalization” could be achieved, for 
instance with the use of temporary vessel obturation 
with special catheters. The second variant practically 
does not differ from well known HS scheme — adsorp-
tion circle is connected in definite time after initiation 
of intraarterial or any other type of local drug admin-
istration. Presently an ideology of “adsorption barrier” 
is successfully developed in experimentally-clinical 
studies of Japanese scientists who have used HS in the 
process of intraarterial administration of high doses 
of cytostatics under venous isolation, and reported 
on significant improvement of treatment results at the 
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background of decreased systemic concentrations 
of the preparations [27–29].
The development of deliganding adsorbents 
able to provide deep blood purification from free 
and protein-bound compounds to which belong 
many anticancer cytostatics, opens the perspective 
of generation of potent barrier limiting their appear-
ance in systemic blood circulation or minimizing the 
period of their presence in blood. Sorption system 
on the basis of deliganding adsorbents, i.e. so-called 
“quick sorption system”, is able to provide durable 
decrease of systemic concentration of cytostatics 
and their toxic effects and the apparatus may be con-
nected not only to venous collectors in an area injured 
by tumor but in any point of systemic blood flow. This 
is extremely important in such clinical situations when 
a possibility to perform regional chemotherapy for 
removal of cytostatics excess from blood is absent 
in principle. For realization of this approach there 
is required the sorption system that allows effectively 
treat nearly 1–2 l of blood per minute, i.e. the one close 
by its efficiency to apparatus “heart-lungs”. All main 
components required for creation of such system (min-
iature rotor pumps that do not traumatize blood cells, 
deliganding adsorbents, systems for control of perfu-
sion parameters and patients’ defense) already exist 
and could be easily united in a single device. Then 
there’ll be created an absolutely new type of cancer 
chemotherapy where regional intra-arterial adminis-
tration of high and super-high doses of cytostatics will 
be associated with practically total absence of toxic 
effects and safe defense of critical organs.
An important method of adjuvant cancer therapy 
is ES performed in the process of parenteral chemo-
therapy.
It has been proven experimentally that ES without 
decreasing anticancer activity of cytostatics, signifi-
cantly minimizes systemic toxic action of chemother-
apy. In Guerin carcinoma-bearing rats treated by cis-
platin at the background daily administration of carbon 
enterosorbents “Carboline”, histologic structure of tis-
sues of kidneys, liver and spleen has been affected 
at significantly lower degree but the number of tumor 
cells at apoptotic state was significantly higher than 
that in tumors of animals treated with chemotherapy 
in the absence of ES. A useful property of “Carboline” 
is its ability to bind effectively bacterial endotoxins 
[30], translocation of which from intestines is drasti-
cally elevated in the process of intense chemotherapy.
Massive ES has recommended itself as a safe 
method of jugulation of symptoms of gastroenteropa-
thy and cytostatic-related myelodepression. Starting 
from the first days of enterosorbent administration, 
an intensity of nausea, vomiting, diarrhea, attenuates 
is diminished and the terms of restoration of leucopoi-
esis are reduced by 1.5–2 times. In patients with differ-
ent forms of malignant neoplasia the use of “Carboline” 
after each course of polychemotherapy, in particular 
that with platinum drugs, allows to prevent severe toxic 
consequences related to the III-rd degree of toxicity, 
and decrease the number of patients whose state 
is characterized by the II-nd degree of toxicity [31]. 
Delayed emethogenic toxicity when nausea and vomit-
ing start from the 3rd day after infusion of anticancer 
drugs, is observed practically in a half of the patients 
while at the background of ES — not more than in 5%.
In general it’s necessary to note that in patients 
with completely depleted possibilities for cytostatic 
therapy, combination of HS and ES directed on the 
prevention of fatal toxic reactions, practically always 
allows to perform at least one more full-scale course 
of anticancer treatment.
Carbon adsorbents in radiation therapy
The picture of structural and metabolic alterations 
observed in cancer patients after extended-field 
radiotherapy, is similar to that upon acute radiation 
sickness of medium severity degree. In this regard 
one could analyze the experimental data obtained 
during HS performance in dogs that received minimal 
absolutely lethal radiation dose. Survival of animals 
in the group treated with intravenous administration 
of antibiotics and albumin solution yielded just 3.2% vs. 
68.4 and 62.4% in animals treated with HS for 2 h and 
24 h after irradiation respectively [32]. Positive clinical 
results were obtained when HS has been applied for 
prophylaxis of post-irradiation reactions in patients 
with Hodgkin’s lymphoma after extended-field and 
subtotal irradiation. In total, HS performed at early 
terms after radiation therapy could be considered 
as an effective method of detoxifying therapy.
ES is not so a quick-acting and effective method 
of detoxification at post-irradiation period, but it could 
be used successfully as myeloprotective means. Bi-
weekly ES course has allowed to increase leucocyte 
blood counts in patients with Hodgkin’s lymphoma 
at average by 2 fold compared with control group. 
There the percent of patients whose leukocyte num-
bers were higher than 4 х 109/ml was 3 fold higher and 
those with leukocyte numbers 2–3 х 109/ml –2 fold 
lower after ES course then after conventional detoxify-
ing therapy [33].
Development of the means and methods for 
prophylaxis and treatment of local post-irradiation 
complications in cancer patients deserves special 
attention [34].
The use of carbon fibrous adsorbents with im-
mobilized DNA capable to bind antinuclear factors, 
at early stage of radiation injuries results in reduced 
terms of cleaning of radiation ulcer surfaces and ap-
pearance of fresh granulations thus providing a chance 
to intensify radiation therapy. In patients with late ra-
diation injuries in the process of use of these carbon 
composites, progressive decrease of dermatitis signs 
and radiation-related fibrosis is observed, thus accel-
erating the skin plastic performance.
Plastic surgery is among perspective fields for 
use of AS method. In plastic surgery carbon fibrous 
adsorbents could be used for preparation of plastic 
beds and fixation of skin peace, and as well — for 
acceleration of donor place healing. In patients with 
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skin melanoma at 2–5th days after finishing of thermo-
radiotherapy, extended ablation of tumor with the next 
plastics of wound defect has been performed with 
splitted perforated skin graft. The use of carbon fibrous 
adsorbents allowed to decrease by more than 90% the 
number of cases of skin graft rejection and by more 
than 30% — the number of complications related 
to necrotic changes in the graft. The terms of complete 
healing have been reduced by 1.5–3 folds [35].
So, the methods of adsorption therapy in oncologic 
clinics could be used for jugulation of intoxication 
before treatment and in the process of therapy for pre-
vention of complications and for elevation of treatment 
efficacy, for therapy of post-surgical purulent-inflam-
matory complications and consequences of chemo- 
and radiation therapy, and improvement of quality 
of life of patients with incurable tumor process.
PERSPECTIVE USAGE OF CARBON 
ADSORBENTS IN CANCER THERAPY
Along with the development of new generation 
of super active carbon adsorbents and new ap-
proaches for their use, the range of tasks that could 
be solved by sorption therapy expands.
Tumor resistance even to high doses of anticancer 
drugs remains among central problems of modern 
chemotherapy. The clinical experience of the last years 
has shown that just in few days after HC performance, 
the sensitivity of an organism to steroid hormones, 
opiate drugs, insulin, desensitizing preparations, and 
to sulphonamides and antibiotics of penicillin and 
cephalosporin lines significantly elevates. Taking into 
account the general patterns, the study of possibility 
to modify drug resistance in cancer patients using 
modern methods of sorption seems to be promising 
enough.
Characteristic patterns of solid tumors, in par-
ticular, increased vascular permeability for circulating 
macromolecules and low level of their lymphatic clear-
ance due to ineffective lymphatic draining, determine 
predominant accumulation of high molecular weight 
molecules in tumor tissues — the phenomenon known 
as Enhanced Permeability and Retention effect — EPR 
effect [36]. EPR effect is acceptable for macromol-
ecules with molecular weight > 45 kDa, including 
water-soluble biocompatible polymers and blood 
plasma proteins [37, 38]. EPR effect created a basis 
of a passive strategy of targeted delivery of medicinal 
preparations to tumor tissue. Unique transport func-
tions of human serum albumin (HSA) that is capable 
to bind reversibly hydrophobic molecules including 
drugs and to accumulate them in solid tumors allow 
considering it as a carrier of anticancer cytostatics. 
There could be selected three main approaches 
to HSA use in macromolecular systems of targeted 
drug delivery: coupling of low-molecular weight drugs 
to exogenous or endogenous albumin, conjugation 
with bioactive proteins and the technology based 
on drug binding with HSA nanoparticles (so-called 
nanoparticle albumin-bound (NAB) technology) [39, 
40]. Significant enhancement of anticancer activity 
of doxorubicin has been achieved its incorporation 
into the matrix of HSA nanoparticles or by adsorption 
to the HSA nanoparticles’ surfaces [40]. Solvent-
based formulations of taxanes, a highly active class 
of cytotoxic agents, are associated with hypersen-
sitivity reactions. 130 nM nanoparticle of albumin-
bound paclitaxel (nab-paclitaxel) was recently used 
in patients with metastatic breast cancer in whom the 
combined therapy was unsuccessful. In a random-
ized phase III study of metastatic breast cancer, nab-
paclitaxel was found to have improved efficacy and 
safety compared with conventional, solvent-based 
paclitaxel [41]. Among the newest developments one 
should mention the complexes presented by HSA 
nanoparticles loaded with doxorubicin and covalently 
bound to monoclonal antibodies directed against alpha 
v beta 3 integrins, which expression is up-regulated 
in various types of cancer. Prepared complexes have 
shown significantly higher cytotoxic activity in alpha 
v beta 3-positive melanoma cells than that of the free 
drug [42]. Doxorubicin-loaded HSA nanoparticles 
the surface of which is modified by covalent attach-
ment of trastuzumab, have demonstrated a specific 
trastuzumab-based targeting of HER2 overexpressing 
breast cancer cells [43].
At present time there have been worked out the op-
timal technologic conditions for conversion of officinal 
HSA preparation to its activated form by purification 
on HSGD hemosorbents [44]. Activated (deliganded) 
HSA (dHSA) possesses significantly enhanced ac-
ceptor capacity of the main discrete binding centers 
compared with the officinal preparation, and is the per-
spective transport means in a context of modern mac-
romolecular systems of targeted drug delivery. It has 
been shown that complex-forming ability of dHSA 
toward cisplatin (CP) is 1.5–1.7-fold higher than that 
of officinal HSA preparation [45]. Comparative evalu-
ation of pharmacokinetics of CP and CP in complex 
with dHSA in Guerin carcinoma-bearing rats has shown 
that upon intravenous administration of the complex, 
it differs by prolonged period of presence in blood flow, 
higher bioavailability, gradual accumulation in tumor 
and kidneys.
Experimental and clinical data have shown that 
anticancer activity of widely used cytostatic — cis-
platin, is determined not only by its free fraction, but 
also by the one bound with albumin; so, one could 
propose a way to elevate antitumor activity of the cy-
tostatic: deep adsorption deligandization of albumin 
prior to chemotherapy initiation that leads to activa-
tion of complex-forming function of the protein that 
at optimal conditions is capable to bind up to 98% 
of administered. Such approach is available also for 
protein-bound anticancer cytostatics, including doxo-
rubicin, adryamycin, metotrexate, etc.
Another perspective field of cancer therapy 
is based of modulating intervention into metabolic rela-
tions between tumor and host by removal of essential 
aminoacids, for instance, L-tryptophane, 80% of which 
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is bound with blood serum albumin. Dr R. Bambauer 
(Germany) has decreased L-tryptophane content 
in blood of cancer patients by 50–60% using multiple 
HS sessions, and has achieved clinically significant 
regression in 21% of the patients, and in 14% of the 
patients — complete elimination of primary tumor 
lesion and metastases [46]. It’s necessary to note 
that all the patients have been ascribed by ethic com-
mission as completely futureless for further surgical 
treatment, chemo- and radiotherapy. Let’s note also 
that HSGD sorbents are at least ten times more effec-
tive for L-tryptophane removal than activated carbons 
of Gambro company (Sweden), that have been used 
by Dr. R. Bambauer in his studies [47].
Thus, the newest carbon adsorbents occupy a no-
table place in combined therapy of cancer patients and 
possess undoubted potential for further expansion 
of their application in cancer treatment.
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